GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » EPS (Diluted)

Windlas Biotech (NSE:WINDLAS) EPS (Diluted) : ₹27.89 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech EPS (Diluted)?

Windlas Biotech's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹8.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27.89.

Windlas Biotech's EPS (Basic) for the three months ended in Mar. 2024 was ₹8.17. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27.97.

Windlas Biotech's EPS without NRI for the three months ended in Mar. 2024 was ₹8.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27.89.

During the past 12 months, Windlas Biotech's average EPS without NRIGrowth Rate was 41.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 14.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Windlas Biotech's highest 3-Year average EPS without NRI Growth Rate was 40.40% per year. The lowest was 14.90% per year. And the median was 24.20% per year.


Windlas Biotech EPS (Diluted) Historical Data

The historical data trend for Windlas Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech EPS (Diluted) Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial 7.44 4.86 18.58 19.70 27.88

Windlas Biotech Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 5.79 6.75 7.26 8.09

Competitive Comparison of Windlas Biotech's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windlas Biotech's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's PE Ratio falls into.



Windlas Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Windlas Biotech's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(581.87-0)/20.871
=27.88

Windlas Biotech's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(169.93-0)/21.035
=8.08

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windlas Biotech  (NSE:WINDLAS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Windlas Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Windlas Biotech (NSE:WINDLAS) Business Description

Traded in Other Exchanges
Address
Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulations contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech (NSE:WINDLAS) Headlines

No Headlines